[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-001", "question": "A 14-year-old competitive swimmer with genotype-positive, phenotype-negative catecholaminergic polymorphic ventricular tachycardia (RYR2 exon 3 p.Arg2474Ser mutation) experiences syncope during a sanctioned meet. Ambulatory monitoring shows bidirectional ventricular tachycardia at 180 bpm during exercise. Baseline QTc is 410 ms. Which long-term pharmacologic strategy is most likely to prevent arrhythmic recurrence?", "options": ["Nadolol 1 mg/kg/day with exercise restriction", "Flecainide 100 mg twice daily as monotherapy", "Nadolol 1 mg/kg/day plus flecainide 100 mg twice daily", "Verapamil 240 mg daily with ICD backup", "ICD implantation with sotalol 120 mg twice daily"], "answer": "C", "answer_index": 2, "explanation": "Specific RYR2 mutations in the channel core (exon 3) demonstrate poor response to beta-blockade alone; combination therapy with flecainide provides synergistic RyR2 stabilization by reducing calcium leak. Verapamil lacks efficacy in CPVT, and ICD shocks can trigger catecholamine surge and arrhythmic storms.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question about managing catecholaminergic polymorphic ventricular tachycardia (CPVT), I need to consider the optimal pharmacologic strategy for this condition.\n\nCPVT is characterized by adrenergically-mediated ventricular arrhythmias, typically triggered by exercise or emotional stress. The RYR2 mutation mentioned is a common genetic cause of CPVT.\n\nFor this patient who was previously phenotype-negative but now has had a clinical event (syncope) with documented bidirectional VT during exercise:\n\nA. Nadolol alone with exercise restriction - Beta-blockers are first-line therapy but may be insufficient after a clinical event.\n\nB. Flecainide monotherapy - Not typically used as monotherapy in CPVT.\n\nC. Nadolol plus flecainide - This combination has shown superior efficacy in CPVT patients who have breakthrough events on beta-blockers alone.\n\nD. Verapamil with ICD backup - Not a standard approach for CPVT.\n\nE. ICD with sotalol - While ICDs may be indicated, they should be combined with optimal medical therapy, and sotalol is not preferred over nadolol for CPVT.\n\nThe combination of a non-selective beta-blocker (nadolol) with flecainide has been shown to be particularly effective in patients with CPVT who have breakthrough events despite beta-blocker therapy alone.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-002", "question": "A 72-hour-old term neonate presents with lethargy and poor feeding. Plasma ammonia is 920 μmol/L, arterial pH 7.32, anion gap 12 mEq/L. Urine orotic acid is undetectable. Plasma amino acids show elevated glutamine with decreased citrulline and arginine. Which intervention directly addresses the primary enzymatic defect?", "options": ["Intravenous sodium phenylbutyrate 250 mg/kg", "Oral carglumic acid 100 mg/kg", "Emergent hemodialysis", "Intravenous arginine HCl 200 mg/kg", "Protein restriction to 0.5 g/kg/day"], "answer": "B", "answer_index": 1, "explanation": "Carbamoyl phosphate synthetase I deficiency is uniquely responsive to carglumic acid, which allosterically activates the defective enzyme by increasing its affinity for N-acetylglutamate. Sodium phenylbutyrate and arginine require functional CPS1 activity to excrete nitrogen and are ineffective. Hemodialysis is temporizing but not disease-specific.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To determine the best intervention, I need to identify the primary enzymatic defect based on the clinical presentation.\n\nThe key findings are:\n- Severe hyperammonemia (920 μmol/L)\n- Undetectable urine orotic acid\n- Elevated glutamine\n- Decreased citrulline and arginine\n- Normal anion gap\n\nThese findings are consistent with a urea cycle disorder, specifically carbamoyl phosphate synthetase I (CPS-I) deficiency or N-acetylglutamate synthase (NAGS) deficiency. The absence of orotic aciduria helps distinguish these from other urea cycle disorders like ornithine transcarbamylase deficiency.\n\nLet's evaluate each option:\n\nA. Sodium phenylbutyrate - This provides an alternative pathway for nitrogen excretion but doesn't address the primary enzymatic defect.\n\nB. Carglumic acid - This is a structural analog of N-acetylglutamate (NAG), which is an essential activator of CPS-I. In NAGS deficiency, carglumic acid directly addresses the primary enzymatic defect by replacing the missing activator.\n\nC. Hemodialysis - This removes ammonia but doesn't address the enzymatic defect.\n\nD. Arginine HCl - This helps restore downstream urea cycle intermediates but doesn't address the primary defect.\n\nE. Protein restriction - This reduces nitrogen load but doesn't address the enzymatic defect.\n\nGiven the biochemical profile and the absence of orotic acid, NAGS deficiency is most likely, and carglumic acid directly addresses this defect.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-003", "question": "A 30-year-old diver is stung on the neck by a thumbnail-sized jellyfish off the Great Barrier Reef. Initial pain resolves, but 45 minutes later develops severe lower back pain, dyspnea, and pulmonary edema with systolic BP 190 mmHg. Which therapy specifically antagonizes the pathophysiologic cascade?", "options": ["Chironex fleckeri antivenom 20,000 units IV", "Magnesium sulfate 50 mg/kg IV bolus then infusion", "Calcium gluconate 1 g IV", "Fentanyl 100 μg IV", "Verapamil 5 mg IV"], "answer": "B", "answer_index": 1, "explanation": "Irukandji syndrome from Carukia barnesi triggers massive catecholamine release via voltage-gated sodium channel modulation; magnesium sulfate inhibits catecholamine release and reduces calcium influx at presynaptic terminals. Chironex antivenom is ineffective against Irukandji toxins, while calcium may worsen catecholamine release.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This case describes a severe reaction to a jellyfish sting from the Great Barrier Reef. The delayed onset of symptoms (45 minutes after the sting) with severe lower back pain, respiratory distress, pulmonary edema, and hypertension is characteristic of Irukandji syndrome, caused by Carukia barnesi or related jellyfish species.\n\nThe pathophysiology of Irukandji syndrome involves massive catecholamine release, leading to the hypertension, pulmonary edema, and severe pain. The most effective specific treatment that directly antagonizes this pathophysiologic cascade is magnesium sulfate, which blocks catecholamine release and has vasodilatory effects.\n\nWhile Chironex fleckeri (box jellyfish) antivenom would be appropriate for box jellyfish stings, it is not effective for Irukandji syndrome. Calcium gluconate, fentanyl, and verapamil may provide symptomatic relief but don't specifically target the underlying catecholamine storm.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-004", "question": "An 8-year-old boy presents with recurrent lacunar strokes, livedo racemosa, and systemic vasculitis. Biopsy shows necrotizing vasculitis without immune complex deposition. Immunoglobulins show IgM 28 mg/dL (low). Genetic testing reveals ADA2 biallelic loss-of-function mutations. Which biologic therapy directly interrupts the disease-driving signaling cascade?", "options": ["High-dose prednisone 2 mg/kg/day", "Cyclophosphamide 500 mg/m² monthly", "Etanercept 0.4 mg/kg twice weekly", "Adalimumab 20 mg every 2 weeks", "Anakinra 2 mg/kg daily"], "answer": "D", "answer_index": 3, "explanation": "Deficiency of adenosine deaminase 2 causes uncontrolled type I interferon and TNF-α signaling; TNF inhibition with adalimumab (monoclonal antibody) is superior to etanercept (soluble receptor) which can bind mutant ADA2 and paradoxically worsen inflammation. Anakinra targets IL-1 and is ineffective for DADA2.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to identify which therapy directly interrupts the disease-driving signaling cascade in ADA2 deficiency (DADA2).\n\nThe patient has:\n- Recurrent lacunar strokes\n- Livedo racemosa\n- Systemic vasculitis\n- Necrotizing vasculitis without immune complex deposition\n- Low IgM\n- Confirmed ADA2 biallelic loss-of-function mutations\n\nDADA2 (Deficiency of Adenosine Deaminase 2) is characterized by vasculopathy and inflammation. The disease mechanism involves increased TNF-alpha signaling, which drives the vasculitis and vascular damage.\n\nAmong the options:\n- Prednisone is a corticosteroid with broad anti-inflammatory effects\n- Cyclophosphamide is an alkylating agent that suppresses immune function\n- Etanercept is a TNF-alpha inhibitor (soluble TNF receptor fusion protein)\n- Adalimumab is a TNF-alpha inhibitor (monoclonal antibody)\n- Anakinra is an IL-1 receptor antagonist\n\nSince DADA2 pathophysiology is driven by excessive TNF-alpha signaling, TNF inhibitors (etanercept or adalimumab) would directly interrupt the disease-driving cascade. Between the two TNF inhibitors, etanercept has been more extensively studied and reported in DADA2 literature as an effective targeted therapy.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-005", "question": "A 23-year-old graduate student has persistent fasting glucose 108-115 mg/dL and HbA1c 6.1-6.3% discovered on routine screening. BMI is 22 kg/m², islet autoantibodies are negative, and both parents have mild hyperglycemia. A heterozygous GCK pathogenic variant is identified. Which management strategy is supported by longitudinal natural history data?", "options": ["Metformin 500 mg twice daily", "Glipizide 5 mg daily", "Sitagliptin 100 mg daily", "No pharmacologic therapy", "Basal insulin 0.2 units/kg"], "answer": "D", "answer_index": 3, "explanation": "Glucokinase MODY resets the glucose threshold to ~140 mg/dL but maintains tight regulation around this setpoint; large cohort studies show no increased microvascular or macrovascular complications, making pharmacotherapy unnecessary. Sulfonylureas are ineffective as they don't correct the underlying glucokinase defect.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "To answer this question, I need to consider what we know about GCK mutations and their management based on natural history data.\n\nThe patient has:\n- Mildly elevated fasting glucose (108-115 mg/dL)\n- Slightly elevated HbA1c (6.1-6.3%)\n- Normal BMI (22 kg/m²)\n- Negative islet autoantibodies\n- Family history of mild hyperglycemia in both parents\n- Confirmed heterozygous GCK pathogenic variant\n\nGCK (glucokinase) mutations cause a condition known as maturity-onset diabetes of the young type 2 (MODY2) or GCK-MODY. This is characterized by:\n- Mild, stable, non-progressive fasting hyperglycemia\n- Minimal risk of diabetes complications\n- A reset glucose homeostasis set point\n- No significant response to oral hypoglycemic agents or insulin\n\nLongitudinal natural history data for GCK mutations shows that:\n- The hyperglycemia is present from birth\n- It remains stable throughout life\n- Patients rarely develop diabetes complications\n- Pharmacologic treatment does not significantly change the underlying glucose set point\n- Treatment does not alter the natural course of the condition\n\nBased on this information, the most appropriate management strategy supported by longitudinal natural history data would be no pharmacologic therapy.\n\nThe answer is (D)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-006", "question": "A 65-year-old man with heart failure presents with LV wall thickness 15 mm, global longitudinal strain -8%, and apical sparing ratio 2.5. Serum lambda light chains are 180 mg/L with free light chain difference 150 mg/L. Which regimen has demonstrated survival benefit in stage IIIb AL amyloidosis with cardiac involvement?", "options": ["Bortezomib-cyclophosphamide-dexamethasone", "Daratumumab-bortezomib-dexamethasone", "Orthotopic heart transplant", "Doxycycline 100 mg twice daily", "Tafamidis 61 mg daily"], "answer": "B", "answer_index": 1, "explanation": "The ANDROMEDA trial demonstrated that daratumumab-based regimens achieve rapid and deep hematologic responses, translating to improved cardiac function and survival in high-risk AL amyloidosis. Tafamidis is indicated for transthyretin, not light-chain amyloidosis. Doxycycline remains investigational.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to analyze the treatment options for stage IIIb AL amyloidosis with cardiac involvement.\n\nThe patient has clear evidence of cardiac amyloidosis with:\n- Increased LV wall thickness (15 mm)\n- Reduced global longitudinal strain (-8%)\n- Apical sparing ratio of 2.5 (characteristic of cardiac amyloidosis)\n- Elevated lambda light chains (180 mg/L)\n- High free light chain difference (150 mg/L)\n\nThese findings are consistent with AL (light chain) amyloidosis with significant cardiac involvement, classified as stage IIIb.\n\nLet's evaluate each option:\n\nA. Bortezomib-cyclophosphamide-dexamethasone (CyBorD) - This is a standard regimen for AL amyloidosis that has shown efficacy, but specific survival benefit in stage IIIb cardiac amyloidosis is limited.\n\nB. Daratumumab-bortezomib-dexamethasone - This regimen has shown improved outcomes in AL amyloidosis, including in patients with cardiac involvement, with demonstrated survival benefit even in advanced disease.\n\nC. Orthotopic heart transplant - While sometimes considered, it has not demonstrated clear survival benefit in stage IIIb AL amyloidosis without concurrent stem cell transplant.\n\nD. Doxycycline - Has shown some promise as an adjunctive therapy but has not demonstrated survival benefit as a primary treatment.\n\nE. Tafamidis - This is approved for ATTR amyloidosis, not AL amyloidosis, and would not be appropriate for this patient.\n\nBased on recent clinical trials, daratumumab-based regimens have shown the most promising survival benefits in advanced cardiac AL amyloidosis.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-007", "question": "A 4-day-old neonate exhibits burst-suppression pattern on EEG and multifocal seizures refractory to phenobarbital 40 mg/kg and levetiracetam 50 mg/kg. Targeted epilepsy panel reveals a de novo KCNQ2 gain-of-function mutation. Which anticonvulsant mechanism is most likely to achieve seizure freedom?", "options": ["GABAergic enhancement with clobazam", "Sodium channel blockade with phenytoin", "Sodium channel blockade with carbamazepine", "Synaptic vesicle modulation with brivaracetam", "Ketogenic diet 4:1 ratio"], "answer": "C", "answer_index": 2, "explanation": "Despite KCNQ2 encoding a potassium channel, gain-of-function mutations cause hyperexcitability that paradoxically responds best to sodium channel blockers like carbamazepine, which reduce overall neuronal firing. Phenobarbital and levetiracetam are often ineffective in this channelopathy.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to consider the pathophysiology of KCNQ2 gain-of-function mutations and which anticonvulsant mechanism would best address this specific genetic abnormality.\n\nKCNQ2 encodes the Kv7.2 potassium channel subunit, which forms part of the M-channel that regulates neuronal excitability. A gain-of-function mutation in KCNQ2 would enhance potassium currents, potentially leading to neuronal hyperpolarization and abnormal brain activity.\n\nLet's analyze each option:\n\nA. GABAergic enhancement (clobazam) - While this might help with seizures generally, it doesn't specifically target the underlying potassium channel dysfunction.\n\nB. Sodium channel blockade (phenytoin) - Sodium channel blockers can be effective for KCNQ2-related epilepsies, as they reduce neuronal excitability through a different mechanism than the affected potassium channels.\n\nC. Sodium channel blockade (carbamazepine) - Similar to phenytoin, but carbamazepine has been specifically reported in literature to be particularly effective for KCNQ2-related epilepsies, often achieving seizure freedom even when other medications fail.\n\nD. Synaptic vesicle modulation (brivaracetam) - This mechanism doesn't directly address the potassium channel dysfunction.\n\nE. Ketogenic diet - While helpful in many refractory epilepsies, it's not specifically targeted to KCNQ2 channelopathies.\n\nBased on clinical evidence, sodium channel blockers, particularly carbamazepine, have shown remarkable efficacy in KCNQ2-related epilepsies, often leading to complete seizure control.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-008", "question": "A 36-year-old woman with migraine with aura develops acute right hemiparesis (NIHSS 8) and arrives within 90 minutes of symptom onset. MRI shows anterior temporal lobe T2 hyperintensities and external capsule involvement. Which intervention is contraindicated due to disease-specific pathophysiology?", "options": ["IV tPA 0.9 mg/kg", "Aspirin 325 mg", "Clopidogrel 600 mg", "Supportive care in stroke unit", "Mechanical thrombectomy"], "answer": "A", "answer_index": 0, "explanation": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) involves fragile small vessels with thickened walls and perivascular deposits; thrombolysis carries excessive hemorrhagic risk due to vessel fragility. Mechanical thrombectomy is also contraindicated for lacunar strokes typical in CADASIL.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "To answer this question, I need to analyze the clinical presentation and MRI findings to determine the likely diagnosis and appropriate management.\n\nThe key features in this case are:\n- 36-year-old woman with migraine with aura\n- Acute right hemiparesis (NIHSS 8)\n- MRI showing anterior temporal lobe T2 hyperintensities and external capsule involvement\n- Presentation within 90 minutes of symptom onset\n\nThese MRI findings (anterior temporal lobe and external capsule involvement) are characteristic of CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), which is a genetic small vessel disease. The patient's history of migraine with aura also supports this diagnosis.\n\nIn CADASIL, the pathophysiology involves non-atherosclerotic, non-amyloid angiopathy affecting small vessels. The disease causes progressive damage to small blood vessels due to mutations in the NOTCH3 gene.\n\nFor intervention contraindications:\n- IV tPA carries increased hemorrhagic risk in small vessel diseases like CADASIL\n- Antiplatelet therapy (aspirin, clopidogrel) is generally appropriate\n- Supportive care is always indicated\n- Mechanical thrombectomy targets large vessel occlusions, not the small vessel disease of CADASIL\n\nThe answer is (A)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-009", "question": "A 29-year-old man with lifelong recurrent fevers (>38.5°C), severe abdominal pain, myalgia, and periorbital edema has an identified TNFRSF1A cysteine mutation. Which biologic therapy is preferred over etanercept due to mechanistic considerations?", "options": ["Colchicine 0.6 mg twice daily", "Etanercept 50 mg weekly", "Anakinra 100 mg daily", "Canakinumab 150 mg every 8 weeks", "Tocilizumab 8 mg/kg monthly"], "answer": "C", "answer_index": 2, "explanation": "Tumor necrosis factor receptor-associated periodic syndrome involves misfolded TNFRSF1A that can bind etanercept, forming complexes that prolong inflammation. IL-1 receptor antagonism with anakinra bypasses this mechanism and is first-line therapy. Colchicine is ineffective for TRAPS.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to analyze the patient's condition and the mechanism of action of each therapy.\n\nThe patient has:\n- Recurrent fevers >38.5°C\n- Severe abdominal pain\n- Myalgia\n- Periorbital edema\n- TNFRSF1A cysteine mutation\n\nThis clinical picture with the specific TNFRSF1A mutation indicates Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), an autoinflammatory disorder.\n\nLet's evaluate each option:\n\nA. Colchicine - Primarily effective for Familial Mediterranean Fever, not typically first-line for TRAPS.\n\nB. Etanercept - A TNF inhibitor that has shown some efficacy in TRAPS, but the question asks for a therapy preferred over etanercept.\n\nC. Anakinra - An IL-1 receptor antagonist. In TRAPS, the mutated TNFR1 leads to increased IL-1β production. Anakinra blocks IL-1 signaling, addressing the downstream effects of the TNFRSF1A mutation.\n\nD. Canakinumab - An IL-1β inhibitor that also targets the IL-1 pathway, similar to anakinra.\n\nE. Tocilizumab - An IL-6 receptor antagonist, not typically first-line for TRAPS.\n\nSince TRAPS involves dysregulated IL-1β production downstream of the TNFR1 mutation, IL-1 inhibitors (anakinra or canakinumab) would be mechanistically preferred over etanercept. Between the two IL-1 inhibitors, anakinra has been more extensively studied in TRAPS.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed127", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed127-010", "question": "A 21-year-old woman with hypertension and a 4-cm adrenal mass has plasma normetanephrine 8.2 nmol/L (ref <0.6). Genetic testing reveals a pathogenic SDHB variant. Which preoperative preparation strategy addresses the unique catecholamine synthesis profile of SDH-related tumors?", "options": ["Phenoxybenzamine 10 mg twice daily for 14 days", "Metyrosine 250 mg four times daily for 7 days", "Phenoxybenzamine plus metyrosine for 10-14 days", "Immediate laparoscopic adrenalectomy", "Amlodipine 10 mg daily only"], "answer": "C", "answer_index": 2, "explanation": "SDH-related pheochromocytomas/paragangliomas exhibit high tyrosine hydroxylase activity and catecholamine synthesis rates, requiring both irreversible alpha-blockade (phenoxybenzamine) and catecholamine synthesis inhibition (metyrosine) for adequate preoperative preparation. Alpha-blockade alone may be insufficient for the catecholamine surge.", "generator_model": "kimi-k2-thinking", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to consider the unique catecholamine synthesis profile of SDH-related tumors and the appropriate preoperative management.\n\nSDH (succinate dehydrogenase) mutations, particularly SDHB variants, are associated with pheochromocytomas and paragangliomas with specific biochemical characteristics. These tumors typically produce predominantly norepinephrine (and its metabolite normetanephrine) with minimal epinephrine production. The patient's elevated normetanephrine confirms this pattern.\n\nFor preoperative preparation of pheochromocytomas:\n- Phenoxybenzamine is an alpha-adrenergic blocker that blocks the effects of catecholamines\n- Metyrosine inhibits tyrosine hydroxylase, reducing catecholamine synthesis\n- Combined therapy is often used for difficult cases\n\nFor SDH-related tumors with their high norepinephrine production, alpha blockade with phenoxybenzamine is essential, but adding metyrosine provides additional benefit by directly reducing catecholamine synthesis. This combination therapy (option C) provides the most comprehensive management for the unique catecholamine profile of SDH-related tumors.\n\nThe answer is (C)"}]